Study of MVI-118 Prostate Cancer Vaccine Expands, Adding Site in Seattle

Study of MVI-118 Prostate Cancer Vaccine Expands, Adding Site in Seattle
A Phase 1 study evaluating the MVI-118 cancer vaccine in patients with metastatic prostate cancer is expanding to a third clinical site, the University of Washington in Seattle. The trial is studying whether MVI-118 can be used in combination with androgen deprivation therapy (ADT) to delay treatment resistance and prolong disease control in patients whose prostate cancer has spread to other areas of the body. It is already going in two clinical sites, the University of Wisconsin-Madison and the Rutgers Cancer Institute in New Jersey. "Many patients are reluctant to start chemotherapy treatment, especially if they are feeling well,” Michael Schweizer, MD, principal inv
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *